Compare CTMX & BLW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTMX | BLW |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.2M | 533.4M |
| IPO Year | 2015 | N/A |
| Metric | CTMX | BLW |
|---|---|---|
| Price | $3.89 | $13.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $6.50 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 85.9K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.83% |
| EPS Growth | ★ 50.22 | N/A |
| EPS | 0.24 | ★ 1.81 |
| Revenue | ★ $113,631,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.28 | ★ $7.73 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.40 | $12.35 |
| 52 Week High | $4.62 | $14.26 |
| Indicator | CTMX | BLW |
|---|---|---|
| Relative Strength Index (RSI) | 51.40 | 42.47 |
| Support Level | $3.66 | $13.69 |
| Resistance Level | $4.20 | $13.93 |
| Average True Range (ATR) | 0.24 | 0.12 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 43.84 | 30.99 |
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Blackrock Ltd Duration Income Trust is a diversified investment fund with an investment objective to provide current income and capital appreciation. The Fund's portfolio normally has an average portfolio duration of less than five years. The Fund may invest directly in such securities or synthetically through the use of derivatives.